Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma

NCT05469893 is registered in ClinicalTrials.gov with Irene Ghobrial, MD as lead sponsor.

NCT NCT05469893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05469893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma
Lead sponsor
Irene Ghobrial, MD
Phase
Phase 2
Overall status
Recruiting
Start date
August 10, 2022
Completion date
July 31, 2030
Enrollment
52 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

high-risk smoldering multiple myeloma, multiple myeloma, smoldering multiple myeloma